RxDoctor Payments Data

Nicole Zambory, NP

Adult Health · Westlake, OHNPI 1356995138

Payments from drug & device makers

$6,549in general payments, 2019–2025

Across 386 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$719
  • Takeda Pharmaceuticals U.S.A., Inc.$689
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$445
  • Pfizer$298
  • Sanofi$273
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$6,533100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,549 in reported general payments places this provider in the 90th percentile of 1,184 adult health providers in Ohio.

See all adult health providers in Ohio

Medicare billing

Part B allowed, 2024
$27,748
Medicare patients
234
Services billed
289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin20$38,910
LinzessLinaclotide31$25,713
Mesalamine24$17,474
MotegrityPrucalopride Succinate12$6,151
Budesonide DrBudesonide16$4,350
Ursodiol20$3,791
Omeprazole141$1,875
CholestyramineCholestyramine (With Sugar)12$1,415
Pantoprazole Sodium107$1,368
Azathioprine13$396
Dicyclomine Hcl17$362
Famotidine29$312
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl11$155
Amitriptyline Hcl22$148
Sucralfate12$123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$445$38,91020 claims
AbbVieLinzess$1,709$25,71331 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$689$6,15112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,184 adult health providers in Ohio.

Other adult health in Westlake

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →